The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)
Part of paid clinical trials in Cooperstown, New York.
- Sponsor
- Bassett Healthcare
- Study ID
- NCT07556107
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Acute Kidney Injury
- Infection
- Sepsis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Piperacillin + Tazobactam — DRUGPT Dosing (concealed): PT dosing is standard irrespective of infection severity. 4.5 gm IV loading dose over 30 min, then 4.5 g IV over 4 hr (extended infusion) 6 hrs after the loading dose, and then q 8 hr
- meropenem — DRUGM dosing (concealed): M dosing depends on infection severity. 1 gm loading IV dose over 30 min, then 1 gm IV over 4 hr (extended infusion) q 8 hr (default dosing). Clinician has option to increase to 2 gm IV q 8 hr for severe infections and to decrease back to default dosing if previously chosen higher dosing is no longer deemed indicated.
Study Details
The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.
Key Dates
- First listed
- Apr 29, 2026
- Start date
- Aug 17, 2026
- Status verified
- Aug 2026
- Primary completion
- Jun 30, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 852 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Piperacillin/tazobactamVancomycin plus piperacillin/tazobactam
- Active Comparator: MeropenemVancomycin plus meropenem
Primary Outcome Measure
Serum cystatin C (Scys) [ Time Frame: 7 days ]
Central Contacts
- Jennifer Victory, RN, CCRC607-547-6965
- Aletha Sprague
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Bassett Medical Center | Cooperstown | New York | 13326 | |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | John Williamson, PharmD (PRINCIPAL_INVESTIGATOR) |
| West Virginia University | Morgantown | West Virginia | 26506 | Daphne-Dominique Villanueva, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Cooperstown, NY
Related Studies
- A Study of Facilitators and Barriers to Improve Acute Kidney Injury in Children Through Mobile Health InterventionRecruiting · Duke University · Durham, North Carolina
- Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn RegistryRecruiting · Potrero Medical · Washington D.C., District of Columbia
- Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney InjuryRecruiting · SeaStar Medical · Birmingham, Alabama
- CTSN Embolic Protection TrialRecruiting · Icahn School of Medicine at Mount Sinai · North Little Rock, Arkansas